Latest research on Plaquenil

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites.

Latest findings

The DMARDs combination was either with MTX or with Plaquenil (without MTX). [source, 2015]
There was a significant correlation between age and usage of Plaquenil. [source, 2015]
Treated patients had a statistically significant improvement when compared to the control group that was treated with Prednisone and Plaquenil only [86]. [source, 2015]
Six DMARDs were used in both Saudis and non-Saudis, with no significant difference between these 2 populations for each DMARD; the most frequently used DMARD was MTX followed by hydroxychloroquine sulphate (Plaquenil), Glucocorticoids (Prednisolone), Adalimumab (Humira), Sulfasalazine and Leflunomide (Arava) ( [source, 2015]
A significant correlation between anti-MCV positivity and DMARDs was found with Prednisolone (in the cohort), and with Prednisolone and Plaquenil (among Saudis) ( [source, 2015]
Methotrexate was used 76 times as combination scoring the highest in this respect, followed by Prednisolone, Plaquenil, and anti-TNF, Sulfasalazine, and, Leflunomide. [source, 2015]
The highest combination was between MTX with Plaquenil Prednisolone, followed by MTX with Prednisolone Plaquenil, and MTX with anti-TNF, then Plaquenil with Prednisolone and Leflunomide, then other combinations ( [source, 2015]
Methotrexate and Plaquenil, each was equally distributed between single and combination groups. [source, 2015]
Combined Plaquenil was use 38 times, divided as 26 with MTX and 12 without MTX ( [source, 2015]
); indicating that 1/3 of Plaquenil combined use was without MTX and 2/3 was with MTX, with a significant correlation (P=0.00) between MTX and Plaquenil ( [source, 2015]